Background ^18F-fluorodeoxyglucose （FDG） is the most widely used radiotracer in tumor imaging,but its use for brain gliomas and recurrence is limited by the high ^18F-FDG uptake in normal brain tissue.^11C-methioni...Background ^18F-fluorodeoxyglucose （FDG） is the most widely used radiotracer in tumor imaging,but its use for brain gliomas and recurrence is limited by the high ^18F-FDG uptake in normal brain tissue.^11C-methionine （MET） has low uptake in the normal brain tissue,providing potential advantages over ^18F-FDG.The aim of the study was to investigate the diagnostic value of ^11C-MET compared to ^18F-FDG positron emission tomography and computed tomography （PET/CT） in patients with suspected primary and residual/recurrent gliomas.Methods Eighty paired PET/CT scans using ^11C-MET and 18F-FDG were performed on 44 newly diagnosed patients with suspected gliomas and 36 post-operative patients with suspected residual/recurrent tumors.PET/CT results were evaluated by visual and semiquantitative analysis.The sensitivity,specificity and accuracy for detection of gliomas and residual/recurrent tumors were calculated using visual analysis.Tumor to contralateral normal gray matter （T/G） ratio was calculated for semiquantitative analysis.Results Final pathology of the 44 newly diagnosed patients included 26 gliomas （14 high-grade and 12 low-grade tumors） and 18 non-glioma benign lesions.Residual/recurrent gliomas were verified in 28 patients and excluded in 8/36 post-operative patients by subsequent histopathologic examination and/or clinical follow-up for more than six months.The sensitivity,specificity and accuracy of 11C-MET PET/CT were 88.5%,83.3% and 86.4% for gliomas and 96.4%,87.5% and 94.4% for residual/recurrent gliomas,respectively.The sensitivity,specificity and accuracy of 18F-FDG PET/CT were 50.0%,88.9% and 65.9% for gliomas and 46.4%,100.0% and 58.3% for residual/recurrent gliomas,respectively.11C-MET had a higher sensitivity than 18F-FDG （83.3% vs.33.3%,P=0.031） in low-grade gliomas,but had no significant difference in sensitivity from 18F-FDG for high-grade gliomas （92.9% vs.64.3%,P=0.219）.11C-MET T/G uptake ratios in high-grade gliomas,low-grade gliomas and benign lesions were 1.94±0展开更多
Background Morphologic imaging after radiofrequency ablation （RFA） of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression （LTP） dif...Background Morphologic imaging after radiofrequency ablation （RFA） of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression （LTP） difficult. The aim of this study was to evaluate the efficacy of early ^18F-FDG PET/CT scanning to monitor the effectiveness of RFA in colorectal liver metastases. Methods Twelve patients with 20 metastases were treated with RFA for colorectal liver metastases. They underwent PET/CT within 2 weeks before RFA and within 24 hours after RFA （so termed ＂early PET/CT＂）. PET/CT was repeated at 1, 3, and 6 months, and then every 6 months after ablation. The standard of reference was based on available clinical and radiological follow-up data. Results Early PET/CT revealed total photopenia in 16 RFA-treated metastases, which were found to be without residual tumor on the final PET/CT scan. Three RFA-treated metastases with focal uptake were identified as local tumor progression, which necessitated further treatment. One RFA-treated metastasis with rim-shaped uptake was regarded as inflammation. The results of the early PET/CT scanning were consistent with the findings of the final follow-up. Conclusions PET/CT performed within 24 hours after RFA can effectively detect whether residual tumor exists for colorectal cancer liver metastases. The results can guide further treatment, and may improve the efficacy of RFA.展开更多
Background： Cerebral glucose metabolism changes are always observed in patients suffering from malignant tumors. This preliminary study aimed to investigate the brain glucose metabolism changes in patients with lung ...Background： Cerebral glucose metabolism changes are always observed in patients suffering from malignant tumors. This preliminary study aimed to investigate the brain glucose metabolism changes in patients with lung cancer of different histological types. Methods： One hundred and twenty patients with primary untreated lung cancer, who visited People＇s Hospital of Zhengzhou University from February 2012 to July 2013, were divided into three groups based on histological types confirmed by biopsy or surgical pathology, which included adenocarcinoma （52 cases）, squamous cell carcinoma （43 cases）, and small-cell carcinoma （25 cases）. The whole body ^18F-fiuorodeoxyglucose （^18F-FDG） positron emission tomography （PET）/computed tomography （CT） of these cases was retrospectively studied. The brain PET data of three groups were analyzed individually using statistical parametric maps （SPM） software, with 50 age-matched and gender-matched healthy controls for comparison. Results： The brain resting glucose metabolism in all three lung cancer groups showed regional cerebral metabolic reduction. The hypo-metabolic cerebral regions were mainly distributed at the left superior and middle frontal, bilateral superior and middle temporal and inferior and middle temporal gyrus. Besides, the hypo-metabolic regions were also found in the right inferior parietal lobule and hippocampus in the small-cell carcinoma group. The area of the total hypo-metabolic cerebral regions in the small-cell carcinoma group （total voxel value 3255） was larger than those in the adenocarcinoma group （total voxel value 1217） and squamous cell carcinoma group （total voxel value 1292）. Conclusions： The brain resting glucose metabolism in patients with lung cancer shows regional cerebral metabolic reduction and the brain hypo-metabolic changes are related to the histological types of lung cancer.展开更多
AIM To establish patient-individual tumor models of rectal cancer for analyses of novel biomarkers, individual response prediction and individual therapy regimens.METHODS Establishment of cell lines was conducted by d...AIM To establish patient-individual tumor models of rectal cancer for analyses of novel biomarkers, individual response prediction and individual therapy regimens.METHODS Establishment of cell lines was conducted by direct in vitro culturing and in vivo xenografting with subsequent in vitro culturing. Cell lines were in-depth characterized concerning morphological features, invasive and migratory behavior, phenotype, molecular profile including mutational analysis, protein expression, and confirmation of origin by DNA fingerprint. Assessment of chemosensitivity towards an extensive range of current chemotherapeutic drugs and of radiosensitivity was performed including analysis of a combined radioand chemotherapeutic treatment. In addition, glucose metabolism was assessed with 18 F-fluorodeoxyglucose(FDG) and proliferation with 18 F-fluorothymidine.RESULTS We describe the establishment of ultra-low passage rectal cancer cell lines of three patients suffering from rectal cancer. Two cell lines(HROC126, HROC284 Met) were established directly from tumor specimens while HROC239 T0 M1 was established subsequent to xenografting of the tumor. Molecular analysis classified all three cell lines as CIMP-0/non-MSI-H(sporadic standard) type. Mutational analysis revealed following mutational profiles: HROC126: APC^(wt), TP53^(wt), KRAS^(wt), BRAF^(wt), PTEN^(wt); HROC239 T0 M1: APC^(mut), P53^(wt), KRAS^(mut), BRAF^(wt), PTEN^(mut) and HROC284 Met: APC^(wt), P53^(mut), KRAS^(mut), BRAF^(wt), PTEN^(mut). All cell lines could be characterized as epithelial(EpCAM+) tumor cells with equivalent morphologic features and comparable growth kinetics. The cell lines displayed a heterogeneous response toward chemotherapy, radiotherapy and their combined application. HROC126 showed a highly radio-resistant phenotype and HROC284 Met was more susceptible to a combined radiochemotherapy than HROC126 and HROC239 T0 M1. Analysis of 18 F-FDG uptake displayed a markedly reduced FDG uptake of all three cell lines after combined radiochemotherapy.展开更多
AIM To determine the significance and need for investigation of incidental prostatic uptake in men undergoing ^(18)F-labelled fluorodeoxyglucose(^(18)F-FDG) positron emission tomography/computed tomography(PET/CT) for...AIM To determine the significance and need for investigation of incidental prostatic uptake in men undergoing ^(18)F-labelled fluorodeoxyglucose(^(18)F-FDG) positron emission tomography/computed tomography(PET/CT) for other indications.METHODS Hospital databases were searched over a 5-year period for patients undergoing both PET/CT and prostate magnetic resonance imaging(MRI). For the initial analysis, the prostate was divided into six sectors and suspicious or malignant sectors were identified using MRI and histopathology reports respectively. Maximum and mean ^(18)F-FDG standardised uptake values were measured in each sector by an investigator blinded to the MRI and histopathology findings. Two agematched controls were selected per case. Results were analysed using a paired t-test and one-way ANOVA. For the second analysis, PET/CT reports were searched for prostatic uptake reported incidentally and these patients were followed up. RESULTS Over a 5-year period, 15 patients underwent both PET/CT and MRI and had biopsy-proven prostate cancer.Malignant prostatic sectors had a trend to higher ^(18)F-FDG uptake than benign sectors, however this was neither clinically nor statistically significant(3.13 ±0.58 vs 2.86 ± 0.68, P > 0.05). ^(18)F-FDG uptake showed no correlation with the presence or histopathological grade of tumour. ^(18)F-FDG uptake in cases with prostate cancer was comparable to that from age-matched controls. Forty-six(1.6%) of 2846 PET/CTs over a 5-year period reported incidental prostatic uptake. Of these, 18(0.6%) were investigated by PSA, 9(0.3%)were referred to urology, with 3(0.1%) undergoing MRI and/or biopsy. No cases of prostate cancer were diagnosed in patients with incidental ^(18)F-FDG uptake in our institute over a 5-year period.CONCLUSION ^(18)F-FDG uptake overlaps significantly between malignant and benign prostatic conditions. Subsequent patient management was not affected by the reporting of incidental focal prostatic uptake in this cohort.展开更多
基金This study was supported by a grant from the National Natural Science Foundation of China （No. 30870731）.
文摘Background ^18F-fluorodeoxyglucose （FDG） is the most widely used radiotracer in tumor imaging,but its use for brain gliomas and recurrence is limited by the high ^18F-FDG uptake in normal brain tissue.^11C-methionine （MET） has low uptake in the normal brain tissue,providing potential advantages over ^18F-FDG.The aim of the study was to investigate the diagnostic value of ^11C-MET compared to ^18F-FDG positron emission tomography and computed tomography （PET/CT） in patients with suspected primary and residual/recurrent gliomas.Methods Eighty paired PET/CT scans using ^11C-MET and 18F-FDG were performed on 44 newly diagnosed patients with suspected gliomas and 36 post-operative patients with suspected residual/recurrent tumors.PET/CT results were evaluated by visual and semiquantitative analysis.The sensitivity,specificity and accuracy for detection of gliomas and residual/recurrent tumors were calculated using visual analysis.Tumor to contralateral normal gray matter （T/G） ratio was calculated for semiquantitative analysis.Results Final pathology of the 44 newly diagnosed patients included 26 gliomas （14 high-grade and 12 low-grade tumors） and 18 non-glioma benign lesions.Residual/recurrent gliomas were verified in 28 patients and excluded in 8/36 post-operative patients by subsequent histopathologic examination and/or clinical follow-up for more than six months.The sensitivity,specificity and accuracy of 11C-MET PET/CT were 88.5%,83.3% and 86.4% for gliomas and 96.4%,87.5% and 94.4% for residual/recurrent gliomas,respectively.The sensitivity,specificity and accuracy of 18F-FDG PET/CT were 50.0%,88.9% and 65.9% for gliomas and 46.4%,100.0% and 58.3% for residual/recurrent gliomas,respectively.11C-MET had a higher sensitivity than 18F-FDG （83.3% vs.33.3%,P=0.031） in low-grade gliomas,but had no significant difference in sensitivity from 18F-FDG for high-grade gliomas （92.9% vs.64.3%,P=0.219）.11C-MET T/G uptake ratios in high-grade gliomas,low-grade gliomas and benign lesions were 1.94±0
文摘Background Morphologic imaging after radiofrequency ablation （RFA） of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression （LTP） difficult. The aim of this study was to evaluate the efficacy of early ^18F-FDG PET/CT scanning to monitor the effectiveness of RFA in colorectal liver metastases. Methods Twelve patients with 20 metastases were treated with RFA for colorectal liver metastases. They underwent PET/CT within 2 weeks before RFA and within 24 hours after RFA （so termed ＂early PET/CT＂）. PET/CT was repeated at 1, 3, and 6 months, and then every 6 months after ablation. The standard of reference was based on available clinical and radiological follow-up data. Results Early PET/CT revealed total photopenia in 16 RFA-treated metastases, which were found to be without residual tumor on the final PET/CT scan. Three RFA-treated metastases with focal uptake were identified as local tumor progression, which necessitated further treatment. One RFA-treated metastasis with rim-shaped uptake was regarded as inflammation. The results of the early PET/CT scanning were consistent with the findings of the final follow-up. Conclusions PET/CT performed within 24 hours after RFA can effectively detect whether residual tumor exists for colorectal cancer liver metastases. The results can guide further treatment, and may improve the efficacy of RFA.
文摘Background： Cerebral glucose metabolism changes are always observed in patients suffering from malignant tumors. This preliminary study aimed to investigate the brain glucose metabolism changes in patients with lung cancer of different histological types. Methods： One hundred and twenty patients with primary untreated lung cancer, who visited People＇s Hospital of Zhengzhou University from February 2012 to July 2013, were divided into three groups based on histological types confirmed by biopsy or surgical pathology, which included adenocarcinoma （52 cases）, squamous cell carcinoma （43 cases）, and small-cell carcinoma （25 cases）. The whole body ^18F-fiuorodeoxyglucose （^18F-FDG） positron emission tomography （PET）/computed tomography （CT） of these cases was retrospectively studied. The brain PET data of three groups were analyzed individually using statistical parametric maps （SPM） software, with 50 age-matched and gender-matched healthy controls for comparison. Results： The brain resting glucose metabolism in all three lung cancer groups showed regional cerebral metabolic reduction. The hypo-metabolic cerebral regions were mainly distributed at the left superior and middle frontal, bilateral superior and middle temporal and inferior and middle temporal gyrus. Besides, the hypo-metabolic regions were also found in the right inferior parietal lobule and hippocampus in the small-cell carcinoma group. The area of the total hypo-metabolic cerebral regions in the small-cell carcinoma group （total voxel value 3255） was larger than those in the adenocarcinoma group （total voxel value 1217） and squamous cell carcinoma group （total voxel value 1292）. Conclusions： The brain resting glucose metabolism in patients with lung cancer shows regional cerebral metabolic reduction and the brain hypo-metabolic changes are related to the histological types of lung cancer.
基金the German Cancer Foundation to Oliver H Kr?mer,No.KR 2291/7-1
文摘AIM To establish patient-individual tumor models of rectal cancer for analyses of novel biomarkers, individual response prediction and individual therapy regimens.METHODS Establishment of cell lines was conducted by direct in vitro culturing and in vivo xenografting with subsequent in vitro culturing. Cell lines were in-depth characterized concerning morphological features, invasive and migratory behavior, phenotype, molecular profile including mutational analysis, protein expression, and confirmation of origin by DNA fingerprint. Assessment of chemosensitivity towards an extensive range of current chemotherapeutic drugs and of radiosensitivity was performed including analysis of a combined radioand chemotherapeutic treatment. In addition, glucose metabolism was assessed with 18 F-fluorodeoxyglucose(FDG) and proliferation with 18 F-fluorothymidine.RESULTS We describe the establishment of ultra-low passage rectal cancer cell lines of three patients suffering from rectal cancer. Two cell lines(HROC126, HROC284 Met) were established directly from tumor specimens while HROC239 T0 M1 was established subsequent to xenografting of the tumor. Molecular analysis classified all three cell lines as CIMP-0/non-MSI-H(sporadic standard) type. Mutational analysis revealed following mutational profiles: HROC126: APC^(wt), TP53^(wt), KRAS^(wt), BRAF^(wt), PTEN^(wt); HROC239 T0 M1: APC^(mut), P53^(wt), KRAS^(mut), BRAF^(wt), PTEN^(mut) and HROC284 Met: APC^(wt), P53^(mut), KRAS^(mut), BRAF^(wt), PTEN^(mut). All cell lines could be characterized as epithelial(EpCAM+) tumor cells with equivalent morphologic features and comparable growth kinetics. The cell lines displayed a heterogeneous response toward chemotherapy, radiotherapy and their combined application. HROC126 showed a highly radio-resistant phenotype and HROC284 Met was more susceptible to a combined radiochemotherapy than HROC126 and HROC239 T0 M1. Analysis of 18 F-FDG uptake displayed a markedly reduced FDG uptake of all three cell lines after combined radiochemotherapy.
文摘AIM To determine the significance and need for investigation of incidental prostatic uptake in men undergoing ^(18)F-labelled fluorodeoxyglucose(^(18)F-FDG) positron emission tomography/computed tomography(PET/CT) for other indications.METHODS Hospital databases were searched over a 5-year period for patients undergoing both PET/CT and prostate magnetic resonance imaging(MRI). For the initial analysis, the prostate was divided into six sectors and suspicious or malignant sectors were identified using MRI and histopathology reports respectively. Maximum and mean ^(18)F-FDG standardised uptake values were measured in each sector by an investigator blinded to the MRI and histopathology findings. Two agematched controls were selected per case. Results were analysed using a paired t-test and one-way ANOVA. For the second analysis, PET/CT reports were searched for prostatic uptake reported incidentally and these patients were followed up. RESULTS Over a 5-year period, 15 patients underwent both PET/CT and MRI and had biopsy-proven prostate cancer.Malignant prostatic sectors had a trend to higher ^(18)F-FDG uptake than benign sectors, however this was neither clinically nor statistically significant(3.13 ±0.58 vs 2.86 ± 0.68, P > 0.05). ^(18)F-FDG uptake showed no correlation with the presence or histopathological grade of tumour. ^(18)F-FDG uptake in cases with prostate cancer was comparable to that from age-matched controls. Forty-six(1.6%) of 2846 PET/CTs over a 5-year period reported incidental prostatic uptake. Of these, 18(0.6%) were investigated by PSA, 9(0.3%)were referred to urology, with 3(0.1%) undergoing MRI and/or biopsy. No cases of prostate cancer were diagnosed in patients with incidental ^(18)F-FDG uptake in our institute over a 5-year period.CONCLUSION ^(18)F-FDG uptake overlaps significantly between malignant and benign prostatic conditions. Subsequent patient management was not affected by the reporting of incidental focal prostatic uptake in this cohort.
